绥美凯的作用

The role of India's Emcure Pharmaceutical Company: Suimeike Inbec is an antiviral drug. The main function of dolutegravir tablets (Simeike) is to treat AIDS. Dolutegravir can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Due to patent protection restrictions, many drugs are prohibited from being copied in most countries around the world. However, due to the protection of India's special patent laws, Indian Emcure Pharmaceuticals can produce drugs that are almost as effective as the original drugs and have high cost performance.

The ingredients of Suimeikai Inbec are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. Comparing it with patients who failed the first-line treatment of two other integrase inhibitors, RAL (Ascent) and EVG (elvitegravir), Trimeq Inbec has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance.

Suimeikai Inbec was approved by the FDA on August 27, 2014. Subsequently, on January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill compound preparation Suimeiqin Inbec, which is based on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Suimeikai Inbec has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients.

Patients with renal impairment whose creatinine clearance is less than 50mL/min are not recommended to take Inbec treatment. Hepatic Impairment Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Trimax Inbec is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.

Recommended related hot articles: /newsDetail/87215.html